Grimes & Company, Inc. Amicus Therapeutics, Inc. Transaction History
Grimes & Company, Inc.
- $3.66 Billion
- Q3 2024
A detailed history of Grimes & Company, Inc. transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 24,270 shares of FOLD stock, worth $225,711. This represents 0.01% of its overall portfolio holdings.
Number of Shares
24,270
Previous 24,270
-0.0%
Holding current value
$225,711
Previous $240,000
7.92%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding FOLD
# of Institutions
312Shares Held
314MCall Options Held
516KPut Options Held
833K-
Vanguard Group Inc Valley Forge, PA28.8MShares$268 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY28.1MShares$261 Million7.83% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$227 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA24MShares$223 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY23.2MShares$216 Million3.72% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.61B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...